Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253992 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
NCT02253992: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02253992 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 232 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253992, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Urelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 1 |
Why NCT02253992 stopped before completion
NCT02253992 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02253992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02253992 about?
NCT02253992 is a clinical study titled "An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma". The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
What is the current status of trial NCT02253992?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2014-09-29. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT02253992?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Urelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02253992?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02253992's enrollment target sits among peer trials
232 216th of 2000 higher than 1,784 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI